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FINDINGS
Acute HIV infections contribute significantly to the risk of secondary infections since acutely-infected individuals (i.e. during the early sero-conversion period) have very high viral loads and many are unaware of their infection [1, 2] . Current standard-of-care 3 rd generation anti-HIV tests are inadequate to identify a proportion of HIV-infected individuals during the early sero-conversion phase and additional tests to identify HIV p24 antigen or HIV RNA are required [3, 4] . Widespread application of HIV testing and early diagnosis are important to identify HIV-infected individuals to support effective prevention and care. In order to provide counseling regarding the accuracy of the various tests and for planning HIV testing programs, it is important to know the relative effectiveness of HIV point-of-care (POC) vs laboratory-based tests for detecting early seroconversion HIV infections. In Canada, the INSTI TM HIV-1 Antibody Test (bioLytical Laboratories, Richmond BC) is the only licensed POC HIV test and its overall sensitivity and specificity are similar to laboratory-based 3 rd generation enzyme immunoassay (EIA) tests [5] . The manufacturer makes no specific sensitivity claims regarding the early seroconversion phase of HIV infection, but data from testing of 25 sero-conversion panels are available [5] . WB interpretation criteria were: non-reactive (no bands are present); indeterminate (one or more bands are present but the blot does not meet reactive test criteria); reactive [at least two major bands (gp160 and/or gp120; gp41 or p24) must be present]. Cases were excluded if: there was insufficient residual serum for testing; the initial presumptive early seroconversion HIV result was not confirmed by follow-up WB, NAT or physician-reported viral load result; or individuals were known to have advanced HIV disease at diagnosis based on receipt of an AIDS case report within 12 months of a presumptive early sero-conversion HIV result. All subjects gave informed consent for HIV testing. The study was approved by the University of British Columbia Clinical Ethics Review Board.
Sixty-one (61) presumptive early sero-conversion HIV infections were identified, of which eight were excluded (four had insufficient residual serum for testing, two were cases which had no follow-up confirmatory WB testing, and two had an AIDS case report received within 12 months of the presumptive early sero-conversion HIV result). Thus, specimens from 53 individuals were available for analysis. In addition, 10 serum samples from HIV-uninfected individuals (laboratory 3 rd generation EIA non-reactive) were tested, but there was no intent to evaluate the specificity of the INSTI TM assay, which has already been established [5] .
Demographic characteristics of the early sero-conversion HIV cases were: 85% male; mean age 39 years; 95% HIV-1 sub-type B; 71% Caucasian; 59% men who have sex with men (MSM), 25% injection drug user (IDU), and 20% heterosexual, non-IDU (individuals may report more than one exposure category). The demographics of the early seroconversion HIV cases were not significantly different from those of 926 other newly-identified HIV infections diagnosed during the study period, except that the early seroconversion cases were more likely to be MSM [unadjusted odds ratio 1.71; 95% confidence interval (CI) 1.01-2.89]. Of the 53 early sero-conversion HIV specimens, four were laboratory EIA non-reactive but p24 antigen reactive and 49 were laboratory EIA reactive. The laboratory EIA protocol incorporates a 10% grey zone; specimens falling within the grey zone on initial testing are re-tested, and, if still in the grey zone are subjected to confirmatory testing. Louie, et al. [6] reported that of US-licensed rapid and POC HIV tests, the most sensitive assay detected 11/42 (26.2%) early sero-conversion infections. These results may not be directly comparable to those in our study, as the specimens examined by Louie, et al. were selected from acute infections diagnosed by pooled NAT testing of prescreened 1 st generation EIA non-reactive specimens, and might reflect sampling earlier during infection. Our results are consistent with the findings of Giles, et al. [7] , who reported that of 13 simple/rapid HIV test devices, none detected sero-conversion earlier than the most sensitive laboratory EIAs and four performed similarly. Laforgerie, et al. [8] This study has several limitations. Interpretation of results of POC tests performed by trained technologists in a laboratory setting may not be directly generalizable to a clinical setting. It is recognized that necessary quality assurance practices must be in place for accurate POC testing and that non-laboratory or inexperienced health care providers may have difficulties in test result interpretation [10] . A potential source of study bias is that the technologists reading the tests were not blinded to the HIV sero-status of the samples; however, three technologists interpreted each result identically, except for one sample which was read as indeterminate by one technologist and non-reactive by the other two. It is also recognized that individuals with advanced HIV disease may have HIV serological result patterns similar to acute cases, i.e. 3 rd generation EIA reactive, p24 antigen reactive, WB indeterminate. None of the 53 early sero-conversion cases had an associated AIDS report within 12 months of diagnosis; however, due to incomplete and delayed AIDS reporting, it might be feasible that some individuals with advanced HIV infection were mis-classified as early sero-conversion. Given that only residual specimens of known sero-status were assessed, we could not identify individuals with early sero-conversion HIV infection who might have had a reactive INSTI TM test at the same time as, or prior to, a non-reactive laboratory EIA, as has been reported for other POC tests [6] . This analysis involved residual serum, whereas in clinical practice, the INSTI TM POC test uses whole blood which has been shown to provide equivalent results [5] . The study was not designed to assess the overall specificity of the INSTI TM test nor the specificity amongst individuals who present with possible HIV sero-conversion symptoms. The study was carried out using a single batch of INSTI TM tests and the possibility of lot-to-lot variability for the detection of early seroconversion infections cannot be excluded.
In summary, although most early sero-conversion HIV infections in our study were detected by INSTI TM at the time of the initial specimen draw, 20-30% of early-infected individuals would have been missed. At least one 4 th generation POC test, which is able to detect both anti-HIV and p24 antigen, is available and others are in development. Until 4 th generation POC tests are widely adopted and are shown to reliably detect early sero-conversion HIV infection, combining POC testing with laboratory-based NAT or 4 th generation EIA testing could improve detection of early sero-conversion HIV infections in high incidence settings, and this has been recommended by others [3, 4] . 
